pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·43m ago·1 min read
save

Rising health insurance premiums and a private equity hospital chain's shift to nonprofit highlight bleak outlook for US healthcare costs

Sep 28, 2026·read at STAT ↗Negative

Bob Herman's latest Health Care Inc. newsletter warns that employer-sponsored health insurance is becoming increasingly unaffordable, with premiums climbing sharply. The piece cites a series called "Out of Pocket, Out of Reach" that documents how workers are bearing higher costs, and experts predict the situation will worsen in 2027.

The newsletter also notes a notable development: a large private‑equity owned hospital chain has converted to a nonprofit model. While the move may affect the financial structure of the chain, the article frames it as another sign of strain in the broader health‑care system.

Overall, the commentary paints a grim picture of the U.S. health‑care landscape, emphasizing that rising list prices and insurance costs are creating a challenging environment for both patients and providers.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: It really is bleak out there, and list prices matter”

read at STAT ↗
508 words · retrieved 8m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoSTAT+: AbbVie wins FDA nod for Parkinson’s pillSTAT
  • 2h agoSTAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and moreSTAT
  • 3h agoTrump uses ‘contested’ power to cut more funding to HHSSTAT
  • 7h agoOpinion: I discovered a new structure in the heart — just by looking closelySTAT
  • 7h agoOpinion: AI is eroding the barriers that kept biological weapons rareSTAT